PE20010490A1 - Micofenolato mofetil en asociacion con peg-ifn-alfa - Google Patents

Micofenolato mofetil en asociacion con peg-ifn-alfa

Info

Publication number
PE20010490A1
PE20010490A1 PE2000000804A PE0008042000A PE20010490A1 PE 20010490 A1 PE20010490 A1 PE 20010490A1 PE 2000000804 A PE2000000804 A PE 2000000804A PE 0008042000 A PE0008042000 A PE 0008042000A PE 20010490 A1 PE20010490 A1 PE 20010490A1
Authority
PE
Peru
Prior art keywords
mofetile
mycophenolate
ifn
peg
alpha
Prior art date
Application number
PE2000000804A
Other languages
English (en)
Spanish (es)
Inventor
Friederike Zahm
Stephen Christopher Pappas
Mary Catherine Graves
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20010490A1 publication Critical patent/PE20010490A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2000000804A 1999-08-13 2000-08-08 Micofenolato mofetil en asociacion con peg-ifn-alfa PE20010490A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99115950 1999-08-13
US18790700P 2000-03-08 2000-03-08

Publications (1)

Publication Number Publication Date
PE20010490A1 true PE20010490A1 (es) 2001-04-27

Family

ID=29762814

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000804A PE20010490A1 (es) 1999-08-13 2000-08-08 Micofenolato mofetil en asociacion con peg-ifn-alfa

Country Status (14)

Country Link
EP (1) EP1220683A2 (fr)
JP (1) JP2003507339A (fr)
CN (1) CN1368887A (fr)
AU (1) AU7408200A (fr)
BR (1) BR0013252A (fr)
CA (1) CA2380653A1 (fr)
HU (1) HUP0202525A3 (fr)
MX (1) MXPA02001296A (fr)
PE (1) PE20010490A1 (fr)
PL (1) PL357367A1 (fr)
RU (1) RU2002105485A (fr)
TR (1) TR200200401T2 (fr)
WO (1) WO2001012214A2 (fr)
ZA (1) ZA200200280B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
KR20070045244A (ko) * 2004-08-12 2007-05-02 쉐링 코포레이션 안정한 페길화된 인터페론 제형
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
WO2010110503A1 (fr) * 2009-03-27 2010-09-30 주식회사 중외제약 Protéine fusionnée d'interféron-α (ifn-α) comprenant l'ifn-α et un peptide de transduction cytoplasmique (ctp)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583680A3 (fr) 2011-10-21 2013-06-12 Abbvie Inc. Traitement seul (PSI-7977) ou combinatoire dans l'utilisation pour le traitement du VHC
EP3215193B1 (fr) * 2014-11-06 2023-10-04 PharmaEssentia Corporation Régime posologique pour l'interféron pégylé
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Also Published As

Publication number Publication date
WO2001012214A2 (fr) 2001-02-22
JP2003507339A (ja) 2003-02-25
ZA200200280B (en) 2003-04-11
HUP0202525A2 (hu) 2002-11-28
BR0013252A (pt) 2002-04-16
CA2380653A1 (fr) 2001-02-22
CN1368887A (zh) 2002-09-11
WO2001012214A3 (fr) 2001-10-04
AU7408200A (en) 2001-03-13
TR200200401T2 (tr) 2002-06-21
HUP0202525A3 (en) 2003-11-28
MXPA02001296A (es) 2002-07-22
EP1220683A2 (fr) 2002-07-10
RU2002105485A (ru) 2004-01-27
PL357367A1 (en) 2004-07-26

Similar Documents

Publication Publication Date Title
PE20010490A1 (es) Micofenolato mofetil en asociacion con peg-ifn-alfa
PE20001369A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa pegilado
PT1265889E (pt) Medicamentos contra patologias virais
PE20000560A1 (es) Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica
PE119199A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica
UY27069A1 (es) Activadores de glucocinasa del tipo isoindolin-1-ona
PE72799A1 (es) Interferones polietilen glicol modificados
CL2012000421S1 (es) Iluminacion de planta trapecial isoscelica, caras laterales mayores triangulares, convexas y divergentes hacia arriba; la cara superior tiene rebaje trapecial isoscelico con bordes biselados, y en la cara posterior, una pieza en "t" con cilindro inferior, la cara inferior posee amplio rebaje trapecial isoscelico, de lados curvos.
ATE431116T1 (de) Intraokularlinse und injektor dafür
UY29868A1 (es) Nucleocidos 4 modificados como agentes antivirales
PE20010284A1 (es) El uso de un antioxidante con ribavirina para preparar un medicamento para el tratamiento de una infeccion viral
MX9202374A (es) 1,3-oxatiolanos utiles en el tratamiento de hepatitis.
ES2183093T3 (es) Preparacion del 1,1,1,3,3-pentaclorobutano y del 1,1,1,3,3-pentafluorbutano.
ES2098723T3 (es) Material para cojinetes.
ECSP099828A (es) Uso de ranolazina para peptido natriuretico tipo-cerebral elevado
PA8587801A1 (es) Isomeros posicionales de interferon alfa 2-a monopegilado
AR057565A1 (es) Interferon alfa y c- ficocianina para el tratamiento de enfermedades auoinmunes alergicas y cancer
BR0307448A (pt) Preparação liofilizada compreendendo imunocitocinas
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
BR0108997A (pt) Terapia imune adjuvante para hiv
PE61699A1 (es) Composicion farmaceutica de lamivudina
ATE462846T1 (de) Bauteil aus glasbausteinen
DE59105839D1 (de) Grossflächige unterlegscheibe.
AR029557A1 (es) Composicion para el uso en el tratamiento o la prevencion de la mastitis, y uso de oxazolidinona para la fabricacion de un medicamento para el tratamiento o la prevencion de la mastitis
NO20053189L (no) HVC-kombinasjonsterapi.

Legal Events

Date Code Title Description
FD Application declared void or lapsed